Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma.
Apr 2007 - Cancer Immunol. Immunother.; 56(7):0340-7004 [PMID:17131118]
[Yasuda T] [Kamigaki T] [Kawasaki K] [Nakamura T] [Yamamoto M] [Kanemitsu K] [Takase S] [Kuroda D] [Kim Y] [Ajiki T] [Kuroda Y]

Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Nov 2006 - Oncol. Rep.; 16(6):1021-335X [PMID:17089056]
[Yasuda T] [Kamigaki T] [Nakamura T] [Imanishi T] [Hayashi S] [Kawasaki K] [Takase S] [Ajiki T] [Kuroda Y]

Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Apr 2006 - J. Med. Virol.; 78(6):0146-6615 [PMID:16628588]
[Ide F] [Nakamura T] [Tomizawa M] [Kawana-Tachikawa A] [Odawara T] [Hosoya N] [Iwamoto A]

Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.
Sep 2003 - Melanoma Res.; 13(5):0960-8931 [PMID:14512794]
[Nagayama H] [Sato K] [Morishita M] [Uchimaru K] [Oyaizu N] [Inazawa T] [Yamasaki T] [Enomoto M] [Nakaoka T] [Nakamura T] [Maekawa T] [Yamamoto A] [Shimada S] [Saida T] [Kawakami Y] [Asano S] [Tani K] [Takahashi TA] [Yamashita N]